Proportion of patients eligible for adjuvant immunotherapy in nonmetastatic clear-cell renal cell carcinoma treated with radical or partial nephrectomy.

Tanaka, Ryuma; Hatakeyama, Shingo; Miura, Hikari; Hamaya, Tomoko; Yoneyama, Takahiro; Ohyama, Chikara

Tanaka, Ryuma; Hatakeyama, Shingo; Miura, Hikari; Hamaya, Tomoko; Yoneyama, Takahiro; Ohyama, Chikara.

Affiliation

Tanaka R; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hatakeyama S; Department of Urology, Mutsu General Hospital, Mutsu, Japan.
Miura H; Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hamaya T; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Yoneyama T; Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Ohyama C; Department of Urology, Mutsu General Hospital, Mutsu, Japan.

Int J Urol ; 29(10): 1235-1237, 2022 10.

Article de En | MEDLINE | ID: mdl-35697523

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Néphrocarcinome / Tumeurs du rein Limites: Humans Langue: En Journal: Int J Urol Sujet du journal: UROLOGIA Année: 2022 Type de document: Article Pays d'affiliation: Japon Pays de publication: Australie

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google